

After Confirming the Payment, it tooks 2 to 3 working days to deliver.
Delivery via Tcs for All Pakistan.
₨ 573
Brand: MACTER INTERNATIONAL (PVT) LTDGeneric: Glimepiride , Pioglitazone
Pack Size: 14s
Product Form: Tablet
Delivery within: 2 to 3 working days across Pakistan
Glio-P 4/30mg Tablet is a combination medication used in the management of type 2 diabetes mellitus. Each tablet contains 4 mg of Glimepiride and 30 mg of Pioglitazone, two medications that work together to help control blood sugar levels. Glimepiride is a sulfonylurea that enhances the pancreas’s ability to produce insulin, while Pioglitazone is a thiazolidinedione that increases the body’s sensitivity to insulin.
Q: What should I do if I miss a dose of Glio-P? A: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed one.
Q: Can Glio-P be used in combination with other diabetes medications? A: Yes, Glio-P can be used in combination with other diabetes medications as prescribed by your healthcare provider. It is important to follow your doctor’s advice and not make changes to your medication regimen without consultation.
Q: How should Glio-P be stored? A: Store Glio-P at room temperature, away from moisture and heat. Keep it out of reach of children.
Q: What are the symptoms of low blood sugar to watch for? A: Symptoms of hypoglycemia include sweating, trembling, dizziness, confusion, headache, and rapid heartbeat. If you experience these symptoms, check your blood sugar levels and consume a source of glucose.
Q: Is it safe to drive while taking Glio-P? A: Be cautious when driving or operating machinery until you know how Glio-P affects you, especially if you experience symptoms of low blood sugar. It is important to ensure your blood glucose levels are well-managed.
Delivery via Tcs for All Pakistan.
You must be logged in to post a review.
No account yet?
Create an Account
Reviews
There are no reviews yet.